Empirical Antifungal Therapy in Critically Ill Patients

Introduction to Candida Score Limitations

The Infectious Diseases Society of America recommends that the Candida score should not be used as the sole criterion for initiating antifungal therapy in critically ill patients, particularly in COVID-19 patients, due to its significant limitations 1, 2
The Candida score demonstrates high specificity but low sensitivity, meaning it may miss patients who actually have invasive candidiasis, with a sensitivity of 81% and specificity of 74% 5, 6, 7

The presence of multifocal Candida colonization at multiple body sites is a key risk factor for invasive candidiasis 3, 8, 9
Recent broad-spectrum antibiotic exposure is a risk factor for invasive candidiasis 8, 9
Central venous catheters (indwelling) increase the risk of invasive candidiasis 2, 8, 9
Total parenteral nutrition is a risk factor for invasive candidiasis 5, 7, 8
Recent major surgery, particularly abdominal, increases the risk of invasive candidiasis 5, 7, 8
Necrotizing pancreatitis is a risk factor for invasive candidiasis 8, 9
Prolonged ICU stay increases the risk of invasive candidiasis 2, 8
Corticosteroid use is a risk factor for invasive candidiasis 2, 9
Immunocompromised status (neutropenia, transplant, diabetes) increases the risk of invasive candidiasis 8
Dialysis requirement is a risk factor for invasive candidiasis 9

The Infectious Diseases Society of America recommends starting empirical antifungal therapy immediately in critically ill patients with septic shock and risk factors for invasive candidiasis, regardless of Candida score 3, 4, 8
Echinocandins are the preferred empiric therapy for critically ill ICU patients with suspected invasive candidiasis, with a strong recommendation and moderate-quality evidence 3, 10, 4, 8, 9
For critically ill/septic shock patients, echinocandins are mandatory first-line therapy (strong recommendation, moderate-quality evidence) 3, 4, 8
For hemodynamically stable patients without recent azole exposure, fluconazole 800 mg loading then 400 mg daily is acceptable 3, 10, 4

Empirical antifungal therapy should be continued for 2 weeks in patients who improve clinically 3, 10, 4
Therapy can be discontinued at 4-5 days if there is no clinical response to therapy, no subsequent evidence of invasive candidiasis, or negative non-culture-based diagnostic assay with high negative predictive value 3, 4

Delaying antifungal therapy in septic shock waiting for Candida score calculation or culture results can increase mortality, and prompt therapy within 24 hours is associated with a 50% reduction in mortality 3, 8, 9
Relying solely on Candida score in COVID-19 patients is not recommended, as it has not been validated in this population 1, 2
Withholding therapy in patients with clinical sepsis and multiple risk factors based solely on Candida score is not recommended 3, 4
Central venous catheters should always be removed in nonneutropenic patients with candidemia, as this is mandatory, not optional 4, 9